New 'Living Drug' trial targets Tough-to-Treat cancers
NCT ID NCT07399769
First seen Feb 16, 2026 · Last updated Apr 14, 2026 · Updated 9 times
Summary
This study is testing a new type of treatment called MSLN CAR-T cell therapy for people with advanced solid tumors that have spread or come back. Doctors will give a one-time infusion of specially modified immune cells to 20 participants to see if it is safe and if it can help control the cancer. The goal is to see if this approach can reduce tumors in patients who have few other treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANT TUMORS (WITH POSITIVE EXPRESSION OF MSLN IN TUMOR TISSUE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen University General Hospital
RECRUITINGShenzhen, Other (Non U.s.), 518055, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.